Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
Summary
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Official title: IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2025-11-12
Completion Date
2027-09
Last Updated
2025-12-17
Healthy Volunteers
Yes
Conditions
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine
COVID-19 Vaccine, mRNA
Novavax recombinant protein vaccine
Recombinant protein vaccine
Locations (1)
Walter Reed National Military Medical Center
Bethesda, Maryland, United States